Treatment of drug-induced agranulocytosis with haematopoietic growth factors. A review of the clinical experience

BioDrugs

Volumn 11, Issue 3, 1999, Pages 185-200

  Vial, Thierry ^a   Gallant, Cédric ^a   Choquet Kastylevsky, Geneviève ^a   Descotes, Jacques ^a  

^a Centre de Pharmacovigilance   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; AMODIAQUINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; ANTITHYROID AGENT; AZATHIOPRINE; CAPTOPRIL; CLOZAPINE; DAPSONE; DIPYRONE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENOTHIAZINE; PIPERANOMETOZINE; PROCAINAMIDE; QUINIDINE; RANITIDINE; SALAZOSULFAPYRIDINE; TERBINAFINE; TICLOPIDINE; UNINDEXED DRUG; ZIDOVUDINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; BONE PAIN; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; MEDICAL DECISION MAKING; MYALGIA; NEUTROPENIA; OBESITY; PRIORITY JOURNAL; RASH; REVIEW; THROMBOPHLEBITIS; WEIGHT GAIN;

EID: 0032973605     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911030-00005     Document Type: Review

References (110)

1. 1. Schultz W. Über eigenartige Halserkrankungen. Dtsch Med Wochenschr 1922; 48: 1965-50
2. 2. Standardization of definitions and criteria of causality assessment of adverse drug reactions: drug-induced cytopenia [editorial]. Int J Clin Pharmacol Ther Toxicol 1991; 29 (2): 75-81
3. 3. Wiholm BE, Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol 1996; 57 Suppl.: 42-6
4. 4. Heimpel H. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed. Eur J Haematol 1996; 57 Suppl.: 11-5
5. 5. Kaufman DW, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anaemia: monographs in epidemiology and biostatistics. No 18. New York: Oxford University Press, 1991
6. 6. Heimpel H. Drug-induced agranulocytosis. Med Toxicol 1988; 3: 449-62
7. 7. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 1996; 57 Suppl.: 23-30
8. 8. Haas WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
9. 9. Mendelowitz AJ, Gerson SL, Alvir JMJ, et al. Clozapine-induced agranulocytosis; risk factors, monitoring and management. CNS Drugs 1995; 4 (6): 412-21
10. 10. Bertolet BD, White BG, Pepine CJ. Neutropenia occurring during treatment with vesnarinone (OPC-8212). Am J Cardiol 1994; 74: 968-70
11. 11. Furusawa S, Ohashi Y, Asanoi H. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. J Clin Pharmacol 1996; 36 (5): 477-81
12. 12. D'Antonio D, Iacone A, Fioritoni G, et al. Patterns of infections in 41 patients with idiosyncratic drug-induced agranulocytosis. Ann Hematol 1991; 63: 84-8
13. 13. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79: 366-71
14. 14. Abt C, Dietrich M, Niethammer D, et al. Akute Arzneimittel induzierte Agranulocytosis. Dtsch Med Wochenschr 1978; 103: 108-13
15. 15. Jick H, Myers MW, Dean AD. The risk of sulfasalazine-and mesalazine-associated blood disorders. Pharmacotherapy 1995; 15 (2): 176-81
16. 16. Vial T, Pofilet C, Pham E, et al. Agranulocytoses aïgues médicamenteuses: expérience du Centre Régional de Pharmacovigilance de Lyon sur 7 ans. Thérapie 1996; 51 (5): 508-15
17. 17. Salama A, Schutz B, Kiefel V, et al. Immune mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 1989; 72: 127-32
18. 18. Irvine AE, French A, Daly A, et al. Drug-induced neutropenia due to direct effects on CFU-C: ten years of culture experience. Eur J Haematol 1994; 52: 21-7
19. 19. Parent-Massin DM, Sensébé L, Léglise MC, et al. Relevance of in vitro studies of drug-induced agranulocytosis: report of 14 cases. Drug Saf 1993; 9 (6): 463-9
20. 20. Uetrecht JP, Spielberg SP. Mechanisms of neutropenia: the role of neutrophil-specific pathways of drug metabolism. Pharmacoepidemiol Drug Saf 1993; 2 Suppl.: 37-42
21. 21. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by betalactam antibiotics. J Infect Dis 1985; 1: 90-8
22. 22. Rouveix B, Lassoued K, Vittecoq D, et al. Neutropenia due to β-lactamine antibodies. Lancet 1983; 287: 1832-4
23. 23. Bodensteiner DC, Doolittle GC. Adverse haematological complications of anticancer drugs: clinical presentation, management and avoidance. Drug Saf 1993, 8 (3): 213-24
24. 24. Tamai H, Mukuta T, Matsubayashi S, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 1993; 77 (5): 1356-60
25. 25. Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenesis, management and avoidance. Drug Saf 1994; 11 (6): 445-62
26. 26. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (first of two parts). N Engl J Med 1992; 327: 28-35
27. 27. Delannoy A, Géhenot M. Colony-stimulating factor and drug-induced agranulocytosis. Ann Intern Med 1989; 110 (11): 942-3
28. 28. Heinrich B, Gross M, Goebel FD. Methimazole-induced agranulocytosis and granulocyte-colony stimulating factor. Ann Intern Med 1989; 111 (7): 621-2
29. 29. Muroi K, Ito M, Sasaki R, et al. Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor [letter]. Lancet 1989; 11: 55
30. 30. Groopman JE, Feder D. Hematopoietic growth factors in AIDS. Semin Oncol 1992; 19: 408-14
31. 31. Fukuta S, Murakami Y, Kuma K, et al. G-CSF levels during spontaneous recovery from drug-induced agranulocytosis [letter]. Lancet 1993; 342: 1495
32. 32. Tajiri J, Noguchi S, Okamura S, et al. Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern Med 1993; 153: 509-14
33. 33. Demuynck H, Zachée P, Verhoef GEG, et al. Risks of rhG-CSF treatment in drug-induced agranulocytosis. Ann Hematol 1995; 70: 143-7
34. 34. Delannoy A. GM-CSF therapy for drug-induced agranulocytosis. J Intern Med 1992; 231: 269-71
35. 35. Pasquale D, Newton M, Goss JB, et al. Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis. Am J Psychiatry 1996; 153 (11): 1503-4
36. 36. Yokoyama K, Sato T, Nakajima S, et al. Successful treatment of methimazole-induced agranulocytosis by granulocyte colony-stimulating factor. Am J Hematol 1992; 40: 76-7
37. 37. Miyasaka Y, Yoshimura M, Tabata S, et al. Successful treatment of a patient with Graves' disease on hemodialysis complicated by antithyroid drug-induced granulocytopenia and angina pectoris. Thyroid 1997; 7 (4): 621-4
38. 38. Sperner-Unterweger B, Czeipek I, Gaggl S, et al. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF): remission despite continuous treatment with clozapine. Br J Psychiatry 1998, 172: 82-4
39. 39. Hunault M, Dombret H, Gardin C, et al. Hematopoietic growth factors in drug-induced agranulocytosis. Leukemia 1995; 9: 1286-7
40. 40. Hurtado MR, Candelaria MH, Majluf-Cruz A, et al. Drug-induced agranulocytosis treated with granulocyte-macrophage colony-stimulating factor. Rev Invest Clin 1994; 46 (1): 59-61
41. 41 Teitelbaum AH, Bell AJ, Brown SL. Filgrastim (r-metHuG-CSF) reversal of drug-induced agranulocytosis. Am J Med 1993; 95: 245-6
42. 42. Hunt KA, Resnick MP. Clomipramine-induced agranulocytosis and its treatment with G-CSF. Am J Psychiatry 1993; 150 (3): 522-3
43. 43. Sprikkelman A, De Wolf JTM, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 1994; 8 (12): 2031-6
44. 44. Mani S, Barry M, Concato J. Granulocyte-colony stimulating factor therapy in drug-induced agranulocytosis. Arch Intern Med 1993; 153; 2500-1
45. 45. Patton WN, Holyoake TL, Yates JM, et al. Accelerated recovery from drug-induced agranulocytosis following G-CSF therapy. Br J Haematol 1992; 80: 564-5
46. 46. Kendra JR, Rugman FP, Flaherty TA, et al. First use of G-CSF in chlopromazine-induced agranulocytosis: a report of two cases. Postgrad Med J 1993; 69: 885-7
47. 47. Means RT, Sandidge DR, Rankin KM, et al. Treatment of phenothiazine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor [letter]. Am J Hematol 1992; 41: 296
48. 48. Weiss M, Gross-Weege W, Wernet P. Rapid neutrophil recovery from acquired agranulocytosis by recombinant human granulocyte-macrophage colony-stimulating factor in an intensive care patient. Crit Care Med 1992; 20: 1490-1
49. 49. Bauduer F, Mignard D, Ducout L, et al. GM-CSF et agranulocytoses médicamenteuses. Sem Hop 1996; 72 (11-12): 370-2
50. 50. Ellman MH, Telfer MC, Turner AF. Benefit of G-CSF for methotrexate-induced neutropenia in rheumatoid arthritis. Am J Med 1992; 92: 337-8
51. 51. Chia HM, Kalra L, Lakhani AK, et al. Filgrastim for low-dose, captopril-induced agranulocytosis [letter]. Lancet 1993; 342: 304
52. 52. Wallach FR, Zirn J, Murray HW, et al. Use ot granulocyte-macrophage colony-stimulating factor for treatment of drug-inuced agranulocytosis [letter]. Rev Infect Dis 1991; 13: 523
53. 53. Miyagawa S, Shiomi Y, Fukumoto T, et al. Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis. J Am Acad Dermatol 1993; 28 (4): 659-61
54. 54. Martino R, Martinez E, Sureda A, et al. A favorable response to the granulocyte colony-stimulating factor in a patient with agranulocytosis associated with the use of intravenous immunoglobulin. Med Clin 1993; 100: 358-9
55. 55. Gora Tybor J, Krykowski E, Robak T. Treatment of drug-induced agranulocytosis with colony-stimulating factors (G-CSF or GM-CSF). Arch Immunol Ther Exp 1996; 44 (4): 255-8
56. 56. Nand S, Bayer R, Prinz, RA, et al. Granulocyte-macrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991; 37: 267-9
57. 57. Cappellari G, Gaio A, Cavallaro A, et al. Use of colony stimulating factors for the treatment of drug-induced agranulocytosis. Br J Haematol 1993; 84: 183-4
58. 58. Gales BJ, Gales MA. Granulocyte colony-stimulating factor for sulfasalazine-induced agranulocytosis. Ann Pharmacother 1993; 27 (9): 1052-4
59. 59. Kuipers EJ, Vellenga E, de Wolf JTM, et al. Sulfasalazine induced agranulocytosis treated with granulocyte-macrophage colony stimulating factor. J Rheumatol 1992; 19 (4): 621-2
60. 60. Palmblad J, Jonson B, Kanerud L. Treatment of drug-induced agranulocytosis with recombinant GM-CSF. J Intern Med 1990; 228: 537-9
61. 61. Roddie P, Dorrance H, Cook MK, et al. Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor. Aliment Pharmacol Ther 1995; 9: 711-2
62. 62. Rospond RM, Glowacki RC, Mailliard JA. Sargramostim for sulfasalazine-induced agranulocytosis [letter]. Clin Pharm 1993; 12 (3): 179
63. 63. Wyatt S, Joyner MV, Daneshmend TK. Filgrastim for mesalazine-associated neutropenia [letter]. Lancet 1993; 341: 1476
64. 64. Barete S, Bissuel F, Longuet P, et al. Agranulocytosis caused by treatment with terbinafine. Rev Méd Interne 1997; 18 (3): 258-9
65. 65. Kovacs MJ, Alshammari S, Guenther L, et al. Neutropenia and pancytopenia with oral terbinafine [letter]. J Am Acad Dermatol 1994; 31: 806
66. 66. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, et al. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994; 91 (2): 106-7
67. 67. Katz R, Chuang LC, Sutton JD. Use of granulocyte colony-stimulating factor in the treatment of pancytopenia secondary to colchicine overdose. Ann Pharmacother 1992; 26 (9): 1087-8
68. 68. Lopez-Karpovitch X, Ulloa-Aguirre A, von Eiff C, et al. Treatment of methimazole-induced severe aplastic anemia with recombinant human granulocyte-monocyte colony-stimulating factor and glucocorticosteroids. Acta Haematol 1992; 27: 148-50
69. 69. Rawanduzy A, Sarkis A, Rovit RL. Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony-stimulating factor. J Neurosurg 1993; 79: 121-4
70. 70. Tsatalas C, Chalkia P, Garyfallos A, et al. Ticlopidine-induced aplastic anaemia: case report and review of the literature. Clin Drug Invest 1995; 9 (2): 127-30
71. 71. De Jaureguiberry JP, Galzin M, Talard P, et al. Aplasie médullaire associée à la ticlopidine. Rev Méd Interne 1996; 17: 1032-6
72. 72. Escobar-Morreale HF, Bravo P, Garcia-Robles R, et al. Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte macrophage colony stimulating factor. Thyroid 1997; 7 (1): 67-70
73. 73. Kao TW, Hung CC, Chen YC, et al. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Haematol 1997; 98: 211-3
74. 74. Khelif A, Assouline D, Ffrench M, et al. Ticlopidine and aplastic anemia. Br J Haematol 1993; 83: 678-9
75. 75. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28 (10): 1169-71
76. 76. Shapiro CM, Walk D. Aplastic anemia associated with ticopidine. Neurology 1996; 47: 300
77. 77. Delannoy A, Ravoet C. Hematopoietic growth factors in drug-induced agranulocytosis. Leukemia 1995; 9: 1289-90
78. 78. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149-55
79. 79. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. N Engl J Med 1993; 329: 162-7
80. 80. Miller PR, Cutten AEC. Haematological side effects of clozapine: patient characteristics. NZ Med J 1997; 110: 125-7
81. 81. Barnas C, Zwierzina H, Hummer M, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. J Clin Psychiatry 1992; 53 (7): 245-7
82. 82. Bradford CR, Ong EL, Hendrick DJ, et al. Use of colony stimulating factors for the treatment of drug-induced agranulocytosis. Br J Haematol 1993; 84: 182-3
83. 83. Geibig CB, Marks LW. Treatment of clozapine-and molindone-induced agranulocytosis with granulocyte colony-stimulating factor. Ann Pharmacother 1993; 27 (10): 1190-2
84. 84. Gruner U, Pesch S, Spittler S, et al. Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. Dtsch Med Wochenschr 1994; 119: 1467-70
85. 85. Gullion G, Yeh HS. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry 1994; 55 (9): 401-5
86. 86. Lamberti JS, Bellnier TJ, Schwarzkopf SB, et al. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995; 56 (5): 256-9
87. 87. Nielsen-H. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med 1993; 234: 529-31
88. 88. Oren R, Granat E, Shtussberg S, et al. Clozapine-induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. Br J Psychiatry 1993; 162: 686-7
89. 89. Raison CL, Guze BH, Kissell-RL. Successful treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor. J Clin Psychopharmacol 1994; 14 (4): 285-6
90. 90. Valevski A, Modai I, Lahav M, et al. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 1993; 8: 63-5
91. 91. Weide R, Köppler H, Heymanns J, et al. Successful treatment of clozapine induced agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Br J Haematol 1992; 80: 557-9
92. 92. Gerson SL, Gullion G, Yeh HS, et al. Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis [letter]. Lancet 1992; 340: 1097
93. 93. Chengappa KNR, Gopalani A, Haught MK, et al. The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Psychopharmacol Bull 1996; 32 (1): 111-21
94. 94. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996; 15 (1): 53-63
95. 95. Balkin MS, Buchholtz M, Ortiz J, et al. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993; 3 (4): 305-9
96. 96. Björkholm M, Pisa P, Arver S, et al. Haematologic effects of granulocyte-macrophage colony stimulating factor in a patient with thiamazole-induced agranulocytosis. J Intern Med 1992; 232: 443-5
97. 97. Freebairn RC, Young RJ, Gomersall CD, et al. Successful treatment of carbimazole-induced agranulocytosis and severe sepsis with granulocyte macrophage colony stimulating factor. Anaesth Intensive Care 1995; 23 (4): 510-2
98. 98. Genet P, Pulik M, Lionnet F, et al. Use of colony-stimulating factors for the treatment of carbimazole-induced agranulocytosis. Am J Hematol 1994; 47: 334-5
99. 99. Gerl A, Gerhartz H, Wilmanns W. GM-CSF for agranulocytosis. J Intern Med 1991; 230: 90-1
100. 100. Magner JA, Snyder DK. Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1994; 4 (3): 295-6
101. 101. Somogyi A, Rosta A, Lang I, et al. Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor. Adverse Drug React Toxicol Rev 1996; 15 (2): 119-24
102. 102. Willfort A, Lorber C, Kapiotis S, et al. Treatment of drug-induced agranulocytosis with recombinant granulocyte colony-stimulating factor (rh G-CSF). Ann Hematol 1993; 66: 241-4
103. 103. Vial T, Descotes J. Clinical loxicity of cytokines used as haemopoietic growth factors. Drug Saf 1995; 13 (6): 371-406
104. 104. Schilero GJ, Oropello J, Benjamin E. Impairment in gas exchange after granulocyte colony-stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrom. Chest 1995; 107: 276-8
105. 105. Devereux S, Linch DC, Campos Costa D, et al. Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet 1987; 11: 1523-4
106. 106 Bregni M, Siena S, Di Nicola M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high dose cyclophosphamide cancer therapy. J Clin Oncol 1996; 14 (2): 628-35
107. 107. Cabalerro MD, Vazques L, Barragnan JM, et al. Randomised study of filgrastim versus molgramostim after peripheral stem cell transplant in breast cancer. Haematologica 1998; 83: 514-8
108. 108. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 (9 Suppl. B): 139-42
109. 109. Tajiri J, Noguchi S, Murakami N. Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Thyroid 1997; 7 (4): 575-8
110. 110. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidenced-based, clinical practice guidelines. J Clin Oncol 1994; 12 (11): 2471-508